Insider Trading Alert - PFPT, MNTA And STKL Traded By Insiders

Stocks with insider trader activity include PFPT, MNTA and STKL
By TheStreet Wire ,

Yesterday, Nov. 18, 2015, 127 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $235.29 to $228,091,773.00.

Highlighted Stocks Traded by Insiders:

Proofpoint (PFPT) - FREE Research Report

Newell Tracey, who is EVP, Worldwide Sales at Proofpoint, sold 1,000 shares at $71.18 on Nov. 18, 2015. Following this transaction, the EVP, Worldwide Sales owned 14,133 shares meaning that the stake was reduced by 6.61% with the 1,000-share transaction.

The shares most recently traded at $74.82, up $3.64, or 4.86% since the insider transaction. Historical insider transactions for Proofpoint go as follows:

  • 4-Week # shares sold: 1,000
  • 12-Week # shares sold: 32,000
  • 24-Week # shares sold: 73,000

The average volume for Proofpoint has been 620,700 shares per day over the past 30 days. Proofpoint has a market cap of $3.0 billion and is part of the technology sector and computer software & services industry. Shares are up 53.93% year-to-date as of the close of trading on Wednesday.

Proofpoint, Inc. provides threat protection, incident response, regulatory compliance, archiving, governance, eDiscovery, and secure communication solutions worldwide. Currently, there are 14 analysts who rate Proofpoint a buy, no analysts rate it a sell, and 1 rates it a hold.

Exclusive Offer: Get the latest Stock Analysis on PFPT - FREE

TheStreet Quant Ratings

rates Proofpoint as a

sell

. The company's weaknesses can be seen in multiple areas, such as its deteriorating net income, disappointing return on equity, generally high debt management risk and feeble growth in its earnings per share. Get the full

Proofpoint Ratings Report

from

TheStreet Quant Ratings

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Momenta Pharmaceuticals (MNTA) - FREE Research Report

Kaundinya Ganesh Venkataraman, who is Senior V.P., Research at Momenta Pharmaceuticals, sold 216 shares at $17.65 on Nov. 18, 2015. Following this transaction, the Senior V.P., Research owned 387,729 shares meaning that the stake was reduced by 0.06% with the 216-share transaction.

Shea Richard P, who is Svp, Cfo at Momenta Pharmaceuticals, sold 145 shares at $17.65 on Nov. 18, 2015. Following this transaction, the Svp, Cfo owned 143,135 shares meaning that the stake was reduced by 0.1% with the 145-share transaction.

Bishop John E, who is Senior VP, Pharmaceutical Scie at Momenta Pharmaceuticals, sold 312 shares at $17.65 on Nov. 18, 2015. Following this transaction, the Senior VP, Pharmaceutical Scie owned 94,718 shares meaning that the stake was reduced by 0.33% with the 312-share transaction.

Leicher Bruce, who is SVP & General Counsel at Momenta Pharmaceuticals, sold 387 shares at $17.65 on Nov. 18, 2015. Following this transaction, the SVP & General Counsel owned 117,013 shares meaning that the stake was reduced by 0.33% with the 387-share transaction.

Roach James M., who is Senior VP, Development and Chi at Momenta Pharmaceuticals, sold 312 shares at $17.65 on Nov. 18, 2015. Following this transaction, the Senior VP, Development and Chi owned 91,404 shares meaning that the stake was reduced by 0.34% with the 312-share transaction.

The shares most recently traded at $18.02, up $0.37, or 2.05% since the insider transaction. Historical insider transactions for Momenta Pharmaceuticals go as follows:

  • 4-Week # shares sold: 513
  • 12-Week # shares sold: 513
  • 24-Week # shares sold: 39,079

The average volume for Momenta Pharmaceuticals has been 781,200 shares per day over the past 30 days. Momenta Pharmaceuticals has a market cap of $1.2 billion and is part of the health care sector and drugs industry. Shares are up 51.91% year-to-date as of the close of trading on Wednesday.

Momenta Pharmaceuticals, Inc., a biotechnology company, focuses on developing generic versions of complex drugs, biosimilars, and novel therapeutics for oncology and autoimmune diseases. Currently, there are 5 analysts who rate Momenta Pharmaceuticals a buy, 1 analyst rates it a sell, and 1 rates it a hold.

Exclusive Offer: Get the latest Stock Analysis on MNTA - FREE

TheStreet Quant Ratings

rates Momenta Pharmaceuticals as a

hold

. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures and solid stock price performance. However, as a counter to these strengths, we find that the growth in the company's net income has been quite unimpressive. Get the full

Momenta Pharmaceuticals Ratings Report

from

TheStreet Quant Ratings

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

SunOpta (STKL) - FREE Research Report

Greene Douglas, who is Director at SunOpta, bought 50,000 shares at $7.02 on Nov. 18, 2015. Following this transaction, the Director owned 200,543 shares meaning that the stake was boosted by 33.21% with the 50,000-share transaction.

Detlefsen Michael, who is Director at SunOpta, bought 10,000 shares at $9.00 on Nov. 18, 2015. Following this transaction, the Director owned 44,461 shares meaning that the stake was boosted by 29.02% with the 10,000-share transaction.

The shares most recently traded at $7.03, down $1.97, or 28.02% since the insider transaction. Historical insider transactions for SunOpta go as follows:

  • 4-Week # shares bought: 15,000
  • 4-Week # shares sold: 500
  • 12-Week # shares bought: 20,115
  • 12-Week # shares sold: 500
  • 24-Week # shares bought: 22,747
  • 24-Week # shares sold: 5,500

The average volume for SunOpta has been 1.1 million shares per day over the past 30 days. SunOpta has a market cap of $575.2 million and is part of the consumer goods sector and food & beverage industry. Shares are down 40.34% year-to-date as of the close of trading on Wednesday.

SunOpta Inc. sources, processes, packages, and markets natural, organic, and specialty food products in the United States, Canada, Europe, China, and Ethiopia. The company has a P/E ratio of 96.3. Currently, there are 3 analysts who rate SunOpta a buy, no analysts rate it a sell, and 2 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on STKL - FREE

TheStreet Quant Ratings

rates SunOpta as a

hold

. The company's strengths can be seen in multiple areas, such as its growth in earnings per share, increase in net income and good cash flow from operations. However, as a counter to these strengths, we also find weaknesses including a generally disappointing performance in the stock itself, disappointing return on equity and poor profit margins. Get the full

SunOpta Ratings Report

from

TheStreet Quant Ratings

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Loading ...